Scarica l'app Stockscreener
27.84
2.90%
-0.83
Dopo l'orario di chiusura:
28.00
0.16
+0.57%
Precedente Chiudi:
$28.67
Aprire:
$28.81
Volume 24 ore:
401.11K
Relative Volume:
1.11
Capitalizzazione di mercato:
$1.33B
Reddito:
-
Utile/perdita netta:
$-97.70M
Rapporto P/E:
-10.34
EPS:
-2.6925
Flusso di cassa netto:
$-77.89M
1 W Prestazione:
-7.94%
1M Prestazione:
-0.32%
6M Prestazione:
+17.17%
1 anno Prestazione:
+177.84%
Intervallo 1D:
$27.37
$29.84
Intervallo di 1 settimana:
$27.37
$32.30
Portata 52W:
$7.73
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Nome
Rapport Therapeutics Inc
Settore
Industria
Telefono
857-321-8020
Indirizzo
99 HIGH STREET, BOSTON
Compare RAPP vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
27.84 | 1.33B | 0 | -97.70M | -77.89M | -2.6925 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-02 | Iniziato | Wells Fargo | Overweight |
| 2025-11-19 | Iniziato | BTIG Research | Buy |
| 2025-09-16 | Iniziato | Truist | Buy |
| 2025-08-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-04-08 | Iniziato | Citizens JMP | Mkt Outperform |
| 2024-07-02 | Iniziato | Jefferies | Buy |
| 2024-07-02 | Iniziato | Stifel | Buy |
| 2024-07-02 | Iniziato | TD Cowen | Buy |
Mostra tutto
Rapport Therapeutics Inc Borsa (RAPP) Ultime notizie
Why Rapport Therapeutics (RAPP) Is Down 7.9% After RAP-219 China Deal And Shelf Filing - simplywall.st
Q1 EPS Forecast for Rapport Therapeutics Boosted by Analyst - Defense World
(RAPP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives $50.80 Consensus PT from Brokerages - Defense World
Equities Analysts Offer Predictions for RAPP FY2030 Earnings - MarketBeat
Capital International Investors Buys 800,000 Shares of Rapport Therapeutics, Inc. $RAPP - MarketBeat
Day Trade: Will Rapport Therapeutics Inc stock go up in YEARMarket Weekly Review & Scalable Portfolio Growth Methods - baoquankhu1.vn
Rapport Therapeutics (NASDAQ:RAPP) Price Target Raised to $46.00 at Wells Fargo & Company - MarketBeat
Stifel reiterates Rapport Therapeutics stock rating after results By Investing.com - Investing.com Canada
Rapport Therapeutics Inc (RAPP) Reports a Wider Loss for Q4 2025 - AlphaStreet
Rapport Therapeutics Reports Strong 2025 Results, Advances RAP-219 Epilepsy Drug to Phase 3 with $490M Cash Runway - Minichart
Rapport’s RAP-219 gets more phase III funding with Tenacia deal - bioworld.com
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Down on Disappointing Earnings - MarketBeat
Rapport Therapeutics: Advancing Precision Neuroscience with RAP Technology Platform for Neurological and Psychiatric Disorders 4048 - Minichart
Earnings Flash (RAPP) Rapport Therapeutics Posts Q4 Net Loss $0.72 a Share, vs. FactSet Est of $0.70 Loss - marketscreener.com
Rapport Therapeutics (NASDAQ:RAPP) Posts Quarterly Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat
Rapport Therapeutics 2025 10‑K: Net loss $111.5M, EPS $(2.86) - TradingView
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire
Citizens reiterates Rapport Therapeutics stock rating on seizure drug potential By Investing.com - Investing.com Canada
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Maintained Buy: RAPP analyst rating on Rapport Therapeutics, Inc. Common Stock Mar 2026 - Meyka
Top Executive’s Surprise Stock Move Shakes Up Rapport Therapeutics - TipRanks
Cheryl Gault Sells 2,014 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
BTIG reiterates Rapport Therapeutics stock rating citing selectivity By Investing.com - Investing.com Canada
Rapport Therapeutics stock holds Buy at TD Cowen on China deal - Investing.com Canada
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China - Bitget
China rights deal backs new epilepsy, bipolar drug RAP-219 - Stock Titan
How Rapport Therapeutics Inc. stock reacts to bond yieldsJuly 2025 Catalysts & Expert Curated Trade Setup Alerts - Naître et grandir
Published on: 2026-03-07 16:24:29 - baoquankhu1.vn
Is Rapport Therapeutics Inc. stock oversold or undervalued2025 Technical Overview & Weekly High Conviction Trade Ideas - Naître et grandir
Rapport Therapeutics Inc expected to post a loss of 68 cents a shareEarnings Preview - TradingView
Risks Report: Is Rapport Therapeutics Inc a stock for growth or value investorsWeekly Trend Recap & Expert Approved Trade Ideas - baoquankhu1.vn
TD Asset Management Inc Has $4.07 Million Stock Holdings in Rapport Therapeutics, Inc. $RAPP - MarketBeat
Rapport Therapeutics (RAPP) to Release Quarterly Earnings on Tuesday - MarketBeat
RAPP Should I Buy - Intellectia AI
Liquidity Mapping Around (RAPP) Price Events - Stock Traders Daily
RAPP PE Ratio & Valuation, Is RAPP Overvalued - Intellectia AI
Rapport Therapeutics (NASDAQ:RAPP) Raised to Hold at Wall Street Zen - MarketBeat
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Unveiling a 73.63% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Buyout Rumor: What is the cash position of Rapport Therapeutics Inc2025 Macro Impact & Short-Term High Return Ideas - baoquankhu1.vn
Rapport Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Highs Report: What hedge funds are buying Rapport Therapeutics IncGap Down & Consistent Return Investment Signals - baoquankhu1.vn
RAPP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rapport Therapeutics, Inc. (RAPP) Investor Outlook: Analyzing A 70.80% Potential Upside - DirectorsTalk Interviews
Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $246,670.00 in Stock - MarketBeat
Why (RAPP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
RAPP Stock Price and Chart — NASDAQ:RAPP - TradingView
We're Not Very Worried About Rapport Therapeutics' (NASDAQ:RAPP) Cash Burn Rate - Yahoo Finance
Can Rapport Therapeutics Inc. stock deliver surprise earnings beatMarket Sentiment Review & Weekly High Momentum Picks - mfd.ru
RAPP Technical Analysis & Stock Price Forecast - Intellectia AI
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: A Deep Dive Into Its 83% Potential Upside - DirectorsTalk Interviews
Rapport Therapeutics Inc Azioni (RAPP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):